文档介绍：FLAG方案治疗复发或难治性急性髓系白血病临床观察
(作者:___________单位: ___________邮编: ___________)
作者:戴秋新,徐昕,孟文俊,杨建刚,徐茂忠,赵钰
【摘要】目的:探讨FLAG方案治疗复发或难治性急性髓系白血病患者的疗效。方法:采用FLAG方案治疗复发或难治性急性髓系白血病患者37例。FLAG方案为氟达拉滨( Flu) 30mg/m2,dl~d5,阿糖胞苷(AraC) 2g,d1~d5,粒细胞集落刺激因子(GCSF)5μg/kg ×109/L。结果:37例患者中12例完全缓解(CR),%。随访中位总生存期(overall survival, OS)为 ,中位无进展生存期(progressionfreesurvival,PFS)。26例复发患者FLAG方案治疗前少于3个疗程化疗的患者与3个及 3个以上化疗疗程的患者疗效比较,差异有统计学意义()。结论: FLAG方案治疗复发、难治的急性髓系白血病患者效果良好。
【关键词】急性髓系白血病;复发;难治;氟达拉滨
[ABSTRACT] Objective: To study the effect of FLAG program on relapsed or refractory acute myeloid leukemia. Methods:A total of 37 patients with relapsed or refractory acute myeloid leukemia were treated with FLAG program: fludarabine 30 mg/m2
, dld5, AraC 2 g, d1d5, granulocyte colony stimulating factor (GCSF) 5 μg/kg d0 until the white blood cell recovery above × 109 / L. Results: 12 cases plete remission (CR), CR rate was %. The median overall survival (OS) was months, median progress free survival (PFS) was months. There was significant difference between recurrence patients with preFLAG treatment of less than 3 cycles of chemotherapy and patients with three or more cycles of chemotherapy ( ) in 26 cases. Conclusions: FLAG program is a better choice for relapse or refractory patients with acute myelogenous leukemia.

[KEY WORDS] Acute myeloid leuk